Immunotherapy is the use of substances within the body's immune system to inactivate chemicals produced by the tumor to promote its growth. Substances that have been used include different types of interferon, and interleukin-2. While most of these agents have been promising in laboratory studies, they have generally been ineffective in clinical trials in patients with malignant mesothelioma.
The use of interleukin-2 given into the pleural space for patients with early malignant mesothelioma (stage I or II disease) has shown some promise. Several clinical trials are in progress. More information on current trials would be available from the treating physician, the National Cancer Institute, or www.centerwatch.com
The information provided in this site is general in nature and constitutes neither legal nor medical advice. If you are concerned that you or someone you know is at risk of an asbestos-related disease, please consult your physician and an attorney experienced in asbestos litigation cases.
Digg it!
del.icio.us
